Chair of the Board for Studies in English, Belgrade University Faculty of Medicine (BUFM)
|
|
- Opal Norris
- 6 years ago
- Views:
Transcription
1 Prof. Dr. med. Biljana Mihaljevic Chair of the Board for Studies in English, Belgrade University Faculty of Medicine (BUFM) Curriculum Vitae Name Prof. Dr.med. Biljana Mihaljevic Date of Birth 28. I Belgrade, Serbia Address (institutional address): Belgrade University, Faculty of Medicine Dr Subotica 4/2oste Todorovica Belgrade, Serbia Phone: (381 11) Fax:(381 11) Web: Clinic of hematology, Clinical Center Serbia Koste Todorovica 2
2 11000 Belgrade, Serbia Phone/Fax: (381 11) Current Position Director, Clinic for Hematology, Clinical Center Serbia Professor of Internal Medicine, Belgrade University School of Medicine Chair of the Board for Studies in English, Belgrade University Faculty of Medicine (BUFM) Graduate Work, Thesis and Board Certifications , Belgrade University Faculty of Medicine,degree M.D , Oncology, BUFM, degree:mr Sci 1999, Doctorate, BUFM, degree:ph.d , Internal Medicine, BUFM, degree:specialist in Internal Medicine 2008, Hematology, BUFM (2008), degree:subspecialist in hematology Scientific Training 1991/92, British Council Research Fellowship, Prof Daniel Catovsky Laboratory, Royal Marsden Hospital, London, UK 2003, Visiting Proffesor, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Professional Positions , medical doctor, Institute of Onoclogy and Radiology 1988-present, Clinic for hematology, Clinical Center Serbia 2008-present, Director, Clinic for Hematology, CCS , Assistent of Internal medicine, BUFM , Associated Professor of Internal medicine,bufm 2008-present, Full Professor of Internal medicine, BUFM 2015-present. Chair of the Board for Studies in English, BUFM Professional Affiliations Member of the Serbian Hematological Society, Serbian Medical Society , Secretary of the Hematological Society, Serbian Medical Society Founder and President of SLG, Serbian Lymphoma Study Group Member of the Advisory Board SMG, Srbian Multiple Myeloma Group Member of EHA. European Heamtology Association Member of ASH, Americal Society of Hematology
3 Other academic activities ,Chair of CME Board, BUMF 2002-present, Memeber of the CME Board, Rectorate, University of Belgrade Mentor to more than 20 doctorates, masters, subspecialisations Presentations as Guest Speaker to about 100 talks on national and International Conferances, Symosiums, Workshops Scientific focus New drug development and Innovative therapeutical approaches in Lymphomas, Multiple Myeloma and Chronic Lymphocitic Leukemia. Prognostic factors and Molecular basis of non-hodgkins Lymphoma and Chronic Lymphocytic Leukemia Publications in internationally recognized haematological journals Publications (journals,selection) Blood, J Clin Oncol, Haematologica, Lancet Oncol., Med.Oncol., Biomed Pharmacother., Leuk Lymphoma, Clin Lymphoma Myeloma Leuk., Eur J Haematol, Thromb Res, World J Gastroenterol., BMC Immunol... Mihaljevic B, Vukovic V, Smiljanic M, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Jelicic J, Antic D. Single-center experience in the treatment of primary testicular lymphoma. Oncol Res Treat. 2014;37(5): Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, lhan O, Ballova V 1, Hedenus M 1, Hsiao LT 1, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A 1, Fridrik MA, Greil R; AGMT-NHL13 Investigators.Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica Jul;100(7): Krajnović M, Jovanović MP, Mihaljević B, Anđelić B, Tarabar O, Knežević-Ušaj S, Krtolica K. Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease. Clin Transl Sci Oct;7(5): Andjelic B, Antic D, Jakovic L, Todorovic M, Bogdanovic A, Djurasinovic V, Bila J, Mihaljevic B. A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice. Eur J Haematol Nov;93(5): Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, Matovina- Brko G, Hajder J, Matkovic T, Živkovic R, Stanisavljevic N, Todorović M, Petrovic D, Mihaljevic B. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med Mar;25(3): Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, Macdonald D. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol Mar;15(3): Antic D, Petrovic N, Pelemis M, Stevanovic G, Perunicic M, Mihaljevic B. Invisible" primary cutaneous diffuse large B-cell lymphoma, leg type, as a cause of fever of unknown origin. J Clin Oncol Jun 10;31(17):e276-9.
4 Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Filipovic B, Radovanović S, Zdravković M, Stanisavljevic D, Mihaljevic B. c-flip does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.biomed Pharmacother Jun;67(5): Matić IZ, Dorđević M, Dorđić M, Grozdanić N, Damjanović A, Kolundžija B, Vidović A, Bila J, Ristić S, Mihaljević B, Tomin D, Milanović N, Ristić D, Purić M, Gavrilović D, Cordero OJ, Juranić ZD. Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies. Leuk Lymphoma Smiljanic M, Milosevic R, Antic D, Andjelic B,.Djurasinovic V, Todorovic M, Bila J, Bogdanovic A, Mihaljevic B. Orbital and ocular adnexal MALT (Mucosa Associated Lymphoid Tissue) Lymphomas: a single center ten years expirience. Med Oncol,2013 Jaković Lj, Mihaljević B, Peruničić-Jovanović M, Bogdanović A, Andjelić B, Bumbaširević V. Prognostic significance of Bcl-2, Tumor Associated Macrophages, and Total Neoplastic and Inflammatory Lymph node Involvement in Advanced Stage Classical Hodgkin s Lymphoma. Onkologie. 2012;35(12): Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, Colovic M, Colovic N, Vidovic A, Antic D, Mihaljevic B, Pavlovic S, Tosic N. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(4): Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol. 2012; 29(5): Todorovic M, Radisavljevic Z, Balint B, Andjelic B, Todorovic V, Jovanovic MP, Mihaljevic B. Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: a single center study. Appl Immunohistochem Mol Morphol. 2012; 20(5): Andjelic BM, Mihaljevic BS, Jakovic LR. ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years. Pathol Oncol Res. 2012; 18(3): Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Kurtovic NK, Radisavljevic Z, Mihaljevic B. Outcome predictionof advanced mantle cell lymphoma by internationalprognostic index versus different mantle cell lymphoma indexes: one institutuion study. Med Oncol. 2012; 29(3): Antic D, Smiljanic M, Bila J, Jankovic S, Todorovic M, Andjelic B, Mihaljevic B.Hypothalamic dysfunction in a patient with primary lymphoma of the central nervous system., Neurol Sci. 2012;33(2): Andjelic B, Mihaljevic B, Todorovic M, Bila J, Jakovic L, Jovanovic MP. The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma.. Appl Immunohistochem Mol Morphol. 2012; 20(1): Mihaljević BS, Todorović MR, Andjelić BM, Antić DA, Peruničić Jovanović MD. Unusual presentation of gastric plasmoblastic lzmphoma in HIV negative patinet. Med Oncol. 2012, 29 (2): Suvajdzic N, Djurdjevic P, Todorovic M, Perunicic M, Stojanović R, Novkovic A, Mihaljevic B.Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases. Med Oncol. 2012;29(3): Antic D, Mihaljevic B, Cokic V, Fekete MD, Djurasevic TK, Pavlovic S, Milic N, Elezovic I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. Leuk Lymphoma. 2011;52(7): Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. Leuk Lymphoma. 2011;52(10): Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic, Mihaljevic B.Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). Eur J Haematol. 2011;86(3): Lekovic D, Miljic P, Mihaljevic B.Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126(6):
5 Mihaljevic B, Sternic N, Skender Gazibara M, Sretenovic A, Antic D, Terzic T, Kostic V.Intravascular large B-cell lymphoma of central nervous system - a report of two cases and literature review. Clin Neuropathol. 2010;29(4): Trifunovic D, Vujisic-Tesic B, Vuckovic M, Ostojic M, Ristic A, Bogdanovic A, Mihaljevic B, Andjelic B, Perunicic-Jovanovic M, Antonic Z.Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation. Echocardiography. 2010;27(3): Sretenovć A, Antic D, Jankovic S, Gotic M, Perunicic-Jovanovic M, Jakovic L, Mihaljevic B. T- cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Med Oncol ;27(2): Milosevic R, Todorovic M, Balint B, Jevtic M, Krstic M, Ristanovic E, Antonijevic N, Pavlovic M, Perunicic M, Petrovic M, Mihaljevic B. Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma. World J Gastroeneterol. 2009;15(32): Sretenovic M, Colovic M, Jankovic G, Suvajdzic N, Mihaljevic B, Colovic N, Todorovic M, Atkinson MD. More than a third of non-gastric malt lymphomas are disseminated at diagnosis:a single center survey. Eur J Haematol. 2009;82(5): Juranić Z, Radić J, Konić-Ristić A, Jelić S, Mihaljević B, Stanković I, Matković S. Besu I, Gavrilović D. Humoral immunorractivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma. BMC Immunol. 2008;9:22. Djunić I, Jevtović Dj, Ranin J, Salemović D, Tomin D, Mihaljević B. Srbian Lymphoma Study group (SLG): The prognosis of AIDS-related non Hodgkin s Lymphoma. Biomed Pharmacother. 2008;62(1): Mihaljević B, Peruničić Jovanovića M, Jaković Lj, Sretenović A, Bošković D. Hodgkin lymphoma relapse in the uterine cervix 15 years after the initial cure. Med Oncol. 2008;25(2): Jaković Lj, Mihaljević B, Peruničić-Jovanović M., Bogdanović A., Čemerikić Martinović V, Kravić T., Bumbaširević V The Expression of Ki67 and Bcl-2 in Hodgkin s lymphoma: Correlation with the International Prognostic Score and Bulky disease. A study by the Serbian Lymphoma Study Group (SLG). Med Oncol. 2007;24(1): Todorović M, Pavlović M, Balint B, Kraguljac N, Mihaljević B, Bogdanović A, Elezović I, Bosković D, Čolović M Immunophenotype Profile and Clinical Characteristics In Patients with advanced Stage Mantle Cell Lymphoma, Med Oncol. 2007;24(4): Mihaljević B, Jančić-Nedeljkov R., Čemerikić-Martinović V., Babić D., Čolović M. Ki 67 Proliferative marker in lymph Node Aspirates of Patients with Non-Hodgkin's with Non-Hodgkin's Lymphoma. Med Oncol. 2006;23(1): Radojković M., Ristić S., Čolović M., Mihaljević B, Čemerikić-Martinović V Predictive value of prognostic indices in patients with follicular lymphomas. Med Oncol. 2006;23(4): Mihaljević B, Nedeljkov-Jancić R, Vujicić V, Antić D, Janković S, Čolović N Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience. Med Oncol. 2006;23(2): Suvajdžić N, Stanojević-Milenković R, Mihaljević B, Tomašević Z, Čemerikić Z, Atkinson HDE. ALK negative T-cell anaplastic large cell l lymphoma associated with Systemic Lupus Erythematosus. Med Oncol. 2003;20(4): Mihaljević B, Čolović M., Cvetković D., Jovanović V. Solitary intracranial plasmocytomas. Oncol Rep. 1997;4(2): Mihaljević B., Sretenović M., Jančić-Nedeljkov R., Petrović M. Acute megakaryoblastic leukemia with mediastinal tumor. Haematologia. 1996;27(3): Mihaljević B., Donfird M., Jančić-Nedeljkov R., Jovanović V., Petrović M. Angioimmunoblastic lymphadenopathy (AILD) with benign course. Haematologia. 1996;28(1): Buccheri V., Mihaljević B., Matutes E., Dyer M, Mason D., Catovsky D, mb-1: A new marker for B-lineage lymphoblastic leukemia, Blood. 1993;82(3):
6
7
CURRICULUM VITAE EDUCATION:
CURRICULUM VITAE CONTACT: Name: Asst. Prof. Lazar Popović, MD, PhD Licence number: 203866 Date of birth: 23.07.1979. in Novi Sad, Serbia Address: Home: Vojvode Šupljikca 9/31, 21000 Novi Sad Job: Clinic
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationCurriculum vitae NATASA MILIC, MD, PhD
Curriculum vitae NATASA MILIC, MD, PhD BUISINESS ADDRESS Institute for Medical Statistics and Informatics Medical Faculty University of Belgrade Dr Subotica 15, 11000 Belgrade, SERBIA PHONE +381.11.2681964
More informationDuring past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationNon-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationLYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital
LYMPHOMA DIAGNOSIS and PROGNOSIS LC Lim Dept of Hematology Singapore General Hospital OUTLINE Accurate diagnosis Define subtype : WHO classification Staging : Defines extent of involvement Prognosis Determining
More informationContents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
More informationChange Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationLYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
More informationConjunctival CD5+ MALT lymphoma and review of literatures
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Conjunctival CD5+ MALT lymphoma and review of literatures M Fard Citation M Fard. Conjunctival CD5+ MALT lymphoma and review of literatures.
More informationHepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More information2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
More information2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationHODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationSurvivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
Med Oncol (2012) 29:3515 3521 DOI 10.1007/s12032-012-0232-x ORIGINAL PAPER Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL) O. Markovic D. Marisavljevic
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
More informationSmall B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationREPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008
SE Scotland Cancer Network SCAN AUDIT REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 Reports prepared by: Christine Maguire SCAN Cancer Audit Facilitator
More informationPrognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis
Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis Wen-Kai Xia 1, Qing-Feng Lin 2, Dong Shen 2, Zhi-Li Liu 2, Jun Su 2 and Wei-Dong
More informationRoche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma
Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationSHORT C. V. Meletios A. Dimopoulos, MD
SHORT C. V. Meletios A. Dimopoulos, MD Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical at the National and Kapodistrian, Athens, Greece. He has been elected Vice Dean
More informationA 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe
A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe Continuing Medical Education Announcement Harvard Medical School RSS 3081: Monthly BOTSOGO
More informationLymphoma and Myeloma Kris3ne Kra4s, M.D.
Lymphoma and Myeloma Kris3ne Kra4s, M.D. Hematologic Malignancies Leukemia Malignancy of hematopoie3c cells Starts in bone marrow, can spread to blood, nodes Myeloid or lymphoid Acute or chronic Lymphoma
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationRituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More information88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas
More informationCombinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationLymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationRadiation Therapy for Extranodal Lymphomas
Radiation Therapy for Extranodal Lymphomas Keisuke Sasai Masahiko Oguchi Editors Radiation Therapy for Extranodal Lymphomas Editors Keisuke Sasai Department of Radiation Oncology Juntendo University Faculty
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationThe next lymphoma classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno
Evolution of classification The next classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno The Lymphoma Forum of Excellence, Bellinzona, January 2011 Rappaport Lukes and Collins (immunophenotype)
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationPhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA
PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid
More informationPrimary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with
More informationRecent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany
Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma
More informationChronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo
Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas NAIVE -B LYMPHOCYTE MEMORY CELL CLL MCL FL MZL Small cell size Low proliferation
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationLeukemia And Lymphoma In The Nervous System
Leukemia And Lymphoma In The Nervous System If you are searching for the book Leukemia and Lymphoma in the Nervous System in pdf format, then you've come to the right site. We presented complete variant
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationOverview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology
Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from
More informationCase Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent
Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,
More informationFOLLICULARITY in LYMPHOMA
FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!
Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Judith A. Ferry Massachusetts General Hospital Disclosure of Relevant Financial Relationships USCAP requires that all
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationFollicular Lymphoma: the WHO
Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure
More informationFrequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma
Original Article Frequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma Ayaz Lone, 1 Samina Naeem 2 Abstract Introduction: Lymphomas are divided into two, groups Hodgkin s Lymphoma
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationNeoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationLate relapse of Hodgkin s lymphoma is it different in clinical characteristics and outcome?
JBUON 2017; 22(2): 481-486 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Late relapse of Hodgkin s lymphoma is it different in clinical characteristics
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationDETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
More informationClassifications of lymphomas
Classifications of lymphomas Lukes and Collins Kiel classification Working formulation REAL classification (1994) WHO classification (2000) WHO CLASSIFICATIONF OF NEOPLASMS HAEMATOPETIC AND LYMPHOID TISSUES
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More information: Ajou University College of Medicine, Suwon, Korea; Ajou University College of Medicine, Graduate
CURRICULUM VITAE NAME Hyun Woo Lee, M.D. EDUCATION 1991.3.-2001.2 : Ajou University College of Medicine, Suwon, Korea; Doctor of Medicine 2004.3-2006.2 Ajou University College of Medicine, Graduate School,
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationNodular lymphocyte predominant Hodgkin lymphoma. Lymphoma Tumor Board. January 5, 2018
Nodular lymphocyte predominant Hodgkin lymphoma Lymphoma Tumor Board January 5, 2018 Etiology Subtypes of Classical Hodgkin Lymphoma (chl)* Nodular sclerosing HL Most common subtype Composed of large tumor
More information8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls
JBUON 2016; 21(3): 745-749 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com SHORT COMMUNICATION 8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More information